The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP ... 1 or more diabetes complication and frailty. “Regardless, our study provides ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

HealthDay News — For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in ...

The authors used the U.S. Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated a GLP-1 RA and compared them to patients initiating sulfonylureas, dipeptidyl ...

In line with practice-changing trial data, GLP-1 RA reduces cardiovascular and renal outcomes, such as risks for heart failure, chronic kidney disease, acute kidney injury, and major adverse ...